Reply to: Will integrin inhibitors have proangiogenic effects in the clinic?

Nature Medicine

Volumn 15, Issue 7, 2009, Pages 727-

  Reynolds, Andrew R ^a   Hodivala Dilke, Kairbaan M ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CILENGITIDE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; CANCER INVASION; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; GLIOBLASTOMA; HEALTH CARE ORGANIZATION; HEALTH SERVICE; HUMAN; LETTER; METHYLATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOSENSITIZATION; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 67650467692     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0709-727     Document Type: Letter

References (14)

1. Reardon, D.A., Nabors, L.B., Stupp, R. & Mikkelsen, T. Expert Opin. Investig. Drugs 17, 1225-1235 (2008).
2. Welter, M., Reardon, D., Nabors, B. & Stupp, R. Nat. Med. 15, 726 (2009).
3. Brooks, P.C. et al. Cell 79, 1157-1164 (1994).
4. MacDonald, T.J. et al. Neurosurgery 48, 151-157 (2001).
5. Taga, T. et al. Int. J. Cancer 98, 690-697 (2002).
6. Alghisi, G.C., Ponsonnet, L. & Ruegg, C. PLoS One 4, e4449 (2009).
7. Mikkelsen, T. et al. Int. J. Cancer 124, 2719-2727 (2009).
8. Reynolds, A.R. et al. Nat. Med. 15, 392-400 (2009).
9. Caswell, P.T. et al. J. Cell. Biol. 183, 143-155 (2008).
10. Ebos, J.M. et al. Cancer Cell 15, 232-239 (2009).
11. Páez-Ribes, M. et al. Cancer Cell 15, 220-231 (2009).
12. Genentech. http://www.gene.com/gene/news/press-releases/display.do? method=detail&id=12067 (2009).
13. Stupp, R et al. Neuro-oncology 9, 517 (2007).
14. Kamoun, W.S. et al. J. Clin. Oncol. 27, 2542-2552 (2009).